Results 191 to 200 of about 260,498 (362)

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

, 2006
Pedro Cahn, Jorge Villacian, Adriano Lazzarin, Christine Katlama, Beatriz Grinsztejn, Keikawus Arastéh, Pedro Barrera, Nathan Clumeck, J Gerstoft, N.G. Stavrianeas, Santiago Moreno, Francisco Antunes, Dietmar Neubacher, Douglas L. Mayers   +13 more
openalex   +2 more sources

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. [PDF]

Sci Rep, 2020
Bulut H, Hattori SI, Aoki-Ogata H, Hayashi H, Das D, Aoki M, Davis DA, Rao KV, Nyalapatla PR, Ghosh AK, Mitsuya H.   +10 more
europepmc   +1 more source

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV‐infected protease inhibitor‐naive patients

, 2001
Manuel Battegay, Pietro Vernazza, Enos Bernasconi, Markus Flepp, Pedram Sendi, P Erb, R Malinverni, C Jaccard, S Morgenthaler, Véronique Bédoucha, B Hirschel, for the Swiss HIV Cohort Study   +11 more
openalex   +2 more sources

Optimized ACE2‐Fc fusion proteins with picomolar neutralization activity against highly evolved SARS‐CoV‐2 variants

Protein Science, Volume 35, Issue 2, February 2026.
Abstract The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals.
Ferran Abancó, Ferran Tarrés‐Freixas, Rosalba Lepore, Elisa Molina‐Molina, Eloi Franco, Rytis Boreika, Edwards Pradenas, Dàlia Raïch‐Regué, Itziar Erkizia, Bonaventura Clotet, Alfonso Valencia, Júlia Vergara‐Alert, Joaquim Segalés, Jorge Carrillo, Nuria Izquierdo‐Useros, Julià Blanco, Benjamin Trinité   +16 more
wiley   +1 more source

Recent Advances in Heterocyclic HIV Protease Inhibitors. [PDF]

Int J Mol Sci
Funicello M, Chiummiento L, Santarsiere A, Poggio F, Lupattelli P.   +4 more
europepmc   +1 more source

Twenty-eight Year Old HIV Positive Male Patient with Ergotism. Interaction of Ergot-alkaloids and Protease-inhibitors

, 2005
Wolfgang Mlekusch, Martin Schillinger, E Minar   +2 more
openalex   +1 more source

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens [PDF]

, 2005
Susan Swindells, Calvin Cohen, Daniel S Berger, Karen T. Tashima, Qiming Liao, Bonnie Pobiner, Jerry Snidow, Gary E. Pakes, Jaime E. Hernández, the NZTA4008 Study Team   +9 more
openalex   +1 more source

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

Xenobiotica; the fate of foreign compounds in biological systems, 2010
P. Annaert, Zhiwei Ye, Bruno Stieger, P. Augustijns   +3 more
semanticscholar   +1 more source